Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy

At Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, clinical research is centered on respiratory tract diseases and neoplasms, with a strong focus on non-small cell lung cancer and small cell lung cancer. These studies are mainly designed to test new treatment options, compare them with current standards, and improve outcomes for people with advanced or recurrent lung cancer.

• Studies in advanced non-small cell lung cancer, including metastatic and EGFR- or KRAS-driven disease, are evaluating targeted and immune-based therapies.
• Research in early-stage NSCLC is looking at ways to reduce recurrence after surgery and standard treatment.
• Several trials are focused on precision medicine, using tumor markers to match patients with therapies more likely to help.

This area of research reflects a broad effort to refine lung cancer treatment and expand options for patients with difficult-to-treat disease.

The site is also active in small cell lung cancer research, especially for extensive-stage and relapsed disease. These trials aim to improve survival, strengthen disease control, and assess whether new combinations can work better than existing chemotherapy-based approaches.

• Trials in extensive-stage SCLC are testing new maintenance and combination strategies.
• Studies in relapsed SCLC are comparing emerging therapies with established treatment options.
• Research is also examining whether supportive approaches can improve the effectiveness of cancer therapy.

This work highlights a clear focus on improving care for patients with aggressive lung malignancies and limited treatment choices.

A major part of the clinical trial portfolio involves immunotherapy and targeted therapy for non-small cell lung cancer. These studies are designed to determine whether newer immune-based combinations or mutation-directed treatments can improve survival and delay disease progression.

• Research is evaluating immune checkpoint-based combinations for advanced NSCLC.
• Targeted treatment studies are addressing cancers with ALK, ROS1, BRAF, EGFR, and KRAS G12C alterations.
• Some trials compare new therapies directly with widely used standard treatments to measure effectiveness.

This therapeutic area shows a strong commitment to personalized cancer care and the development of more precise treatment strategies.

The research program at this health care site also includes studies for patients with stage IB to IIIA NSCLC after surgery. These trials are focused on preventing recurrence, extending disease-free survival, and improving long-term outcomes after curative treatment.

• Trials are evaluating additional treatment after complete tumor removal in resected NSCLC.
• Research includes patients with EGFR-mutated disease and other high-risk early-stage cancers.
• The main goal is to determine whether post-surgical treatment can better protect against cancer returning.

This work supports better decision-making in lung cancer care after surgery and helps define the role of newer therapies in earlier disease settings.